Gilder Gagnon Howe & Co. LLC Sells 545,914 Shares of Nuvectra Corp (NASDAQ:NVTR)

Gilder Gagnon Howe & Co. LLC reduced its position in Nuvectra Corp (NASDAQ:NVTR) by 68.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 250,411 shares of the company’s stock after selling 545,914 shares during the quarter. Gilder Gagnon Howe & Co. LLC owned approximately 1.40% of Nuvectra worth $341,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Morgan Stanley boosted its position in shares of Nuvectra by 961.3% in the second quarter. Morgan Stanley now owns 641,932 shares of the company’s stock worth $2,151,000 after purchasing an additional 581,444 shares during the period. Renaissance Technologies LLC bought a new position in shares of Nuvectra in the second quarter worth approximately $1,987,000. Royal Bank of Canada lifted its holdings in shares of Nuvectra by 71.5% in the second quarter. Royal Bank of Canada now owns 491,286 shares of the company’s stock worth $1,646,000 after buying an additional 204,777 shares in the last quarter. Penn Capital Management Co. Inc. lifted its holdings in shares of Nuvectra by 14.0% in the second quarter. Penn Capital Management Co. Inc. now owns 334,662 shares of the company’s stock worth $1,121,000 after buying an additional 41,054 shares in the last quarter. Finally, Raffles Associates LP lifted its holdings in shares of Nuvectra by 43.7% in the second quarter. Raffles Associates LP now owns 328,675 shares of the company’s stock worth $1,101,000 after buying an additional 100,000 shares in the last quarter. Institutional investors and hedge funds own 75.17% of the company’s stock.

NVTR stock opened at $0.13 on Thursday. Nuvectra Corp has a one year low of $0.13 and a one year high of $20.85. The company’s fifty day moving average price is $0.69 and its 200-day moving average price is $1.92. The company has a debt-to-equity ratio of 0.58, a quick ratio of 4.42 and a current ratio of 4.86. The company has a market capitalization of $2.33 million, a PE ratio of -0.04 and a beta of 0.69.

Several equities analysts have recently commented on NVTR shares. ValuEngine downgraded shares of Nuvectra from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Zacks Investment Research downgraded shares of Nuvectra from a “buy” rating to a “hold” rating in a report on Wednesday, October 23rd. Finally, Raymond James downgraded shares of Nuvectra from an “outperform” rating to a “market perform” rating in a report on Wednesday, November 13th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. Nuvectra presently has a consensus rating of “Hold” and an average target price of $8.75.

Nuvectra Company Profile

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.

Featured Article: Initial Coin Offerings entail a high degree of risk

Institutional Ownership by Quarter for Nuvectra (NASDAQ:NVTR)

Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit